For Immediate Release

October 31, 2011

Sumitomo Chemical Reports
Consolidated Financial Results
For the Half-Year Ended September 30, 2011
The Sumitomo Chemical Group’s sales for the half-year ended September 30, 2011were ¥998.3 billion, an increase of ¥9.0 billion compared with the same period of theprevious fiscal year. Operating income was ¥54.0 billion, representing an increase
from the first half of the previous fiscal year, but ordinary income, at ¥49.0 billion,
declined from the same period of the previous fiscal year because of lower equity inearnings of affiliates. The Group recorded a net loss of ¥2.7 billion, representing adecline from the first half of the previous year, because of large extraordinary losses
in addition to the decline in ordinary income.
Sumitomo Chemical decided to pay an interim dividend of ¥6 per share.
The Sumitomo Chemical Group’s financial results by business segment for thehalf-year were as follows.
Basic Chemicals
Sales of methyl methacrylate increased due to a rise in overseas market prices. While
market prices rose, sales of raw materials for synthetic fibers declined due todecrease in shipments as a result of the impact of the earthquake. As a result, thesegment’s sales were unchanged from the same period of the previous fiscal year at¥152.3 billion, and operating income improved by ¥0.8 billion, to ¥12.5 billion.
Petrochemicals & Plastics
While domestic shipments of some synthetic resins and petrochemical products
declined as a result of the impact of the earthquake, sales increased overall due tohigher market prices overseas and higher selling prices in Japan, with a sharp rise inprices of naphtha and other feedstocks. As a result, the segment’s sales rose by¥23.5 billion compared with the same period of the previous fiscal year, to ¥341.0
billion, and operating income grew by ¥2.0 billion, to ¥7.8 billion.
IT-related Chemicals
Shipments of polarizing film used in liquid crystal displays (LCDs) rose thanks tohigher demand, but shipments of color filters decreased. In addition to lower sales
prices of both polarizing film and color filters, the value of sales of overseas
subsidiaries decreased in yen terms because of the effects of a stronger yen. As aresult, the segment’s sales declined by ¥15.4 billion compared with the same periodof the previous fiscal year, to ¥148.6 billion, and operating income decreased by ¥7.1billion, to ¥10.1 billion.
Health & Crop Sciences
Sales of the feed additive methionine increased steadily. In the area of crop
protection chemicals, shipments of herbicides remained strong in overseas markets.
Despite the decrease in the value of sales of overseas subsidiaries in yen terms
because of the effects of a stronger yen, the segment’s sales rose by ¥12.7 billion
compared with the same period of the previous fiscal year, to ¥138.5 billion, andoperating income improved by ¥0.4 billion, to ¥14.8 billion.

Pharmaceuticals
The Sumitomo Chemical Group initiated US sales of Latuda® (atypical antipsychotic)
in February 2011. Sales of Avapro® (therapeutic agent for hypertension), Lonasen®
(atypical antipsychotic), and the new drugs Trerief® (therapeutic agent for
Parkinson’s disease) and Metgluco® (biguanide oral hypoglycemic) increased as aresult of continued sales promotion activities. Sales of Amlodin® (therapeutic agentfor hypertension and angina pectoris), however, declined because of competition
with generic drugs. In addition, the value of sales of overseas subsidiaries decreasedin yen terms because of the effects of a stronger yen. As a result, the segment’s sales
declined by ¥11.5 billion compared with the same period of the previous fiscal year, to¥193.2 billion, and operating income increased by ¥0.8 billion, to ¥15.5 billion.
OthersIn addition to the above five segments, the Sumitomo Chemical Group engages insupplying electrical power and steam, providing services for the design, engineering,and construction management of chemical plants, providing transport andwarehousing, and conducting materials and environmental analysis. The segment’ssales were the same as those for the same period of the previous fiscal year, at ¥24.7
billion, and operating income improved by ¥2.6 billion, to ¥3.5 billion.
(Note) Change in Reported Segments Classification Methods
As of April 1, 2011, the Fine Chemicals Segment was eliminated, and functional materials,additives, and dyes that had been included in this segment were transferred to the BasicChemicals Segment. In addition, pharmaceutical chemicals, which had also been included in thissegment, were transferred to the Agricultural Chemicals Segment. Following this change, theAgricultural Chemicals Segment changed its name to the Health & Crop Sciences Segment. The
businesses of consolidated subsidiaries in the Pharmaceuticals Segment that had been includedin the Others Segment were transferred to the Pharmaceuticals Segment.

The Company has revised its consolidated financial forecast of fiscal 2011
announced on July 29, 2011. It now projects its consolidated financial forecast offiscal 2011 to sales of ¥2,020.0 billion, operating income of ¥75.0 billion, ordinary
income of ¥72.0 billion, and net income of ¥10.0 billion. This forecast is based on theassumptions of a foreign exchange rate of ¥77.5/US$ and a naphtha price of¥54,000/kl for the half-year ending March 31, 2012.
For further details, please refer to today’s release titled “Sumitomo ChemicalAnnounces Variances between its Financial Forecast and Actual Results for theHalf-year Ended September 30, 2011 and Revisions to its Financial Forecast for theYear Ending March 31, 2012.”

Summary of Consolidated Results(1) Results of Operations:

Net sales
Operating income
Ordinary income
Income before income taxes
and minority interests
Net (loss) income（\6 Months ended
September 30，2011*1\ Million ）（ US$ 1,000 ）
998,281$ 13,023,888
54,035704,958
48,993
639,178
20,636(2,713)6 Months ended
September 30，2010（ \ Million ）\989,245
53,043
52,107269,224(35,395)

22,5272,515）*1

Net (loss) income per 1,000 shares
Dividends per 1,000 shares:
Interim dividends（\Yen）(1,660)（$\6,000$Comprehensive income（\\ Million ）4,653（\As of September 30, 2011
*1\ Million ）（ US$ 1,000 ）
2,340,351$ 30,532,955
751,8709,809,132

As of March 31, 2011
（ \ Million ）\2,367,314
758,886

6 Months ended
September 30，2011*1\ Million ）（ US$ 1,000 ）
57,162$745,753(60,115)(784,279)(2,578)(33,633)
146,383
1,909,759

6 Months ended
September 30，2010（ \ Million ）\74,757(93,208)
49,359147,772

6 Months ended
September 30，2011*1\ Million ）（ US$ 1,000 ）6 Months ended
September 30，2010*2（ \ Million ）(2) Financial Position:
Total assets
Total net asset(3) Cash Flows:

Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Cash and cash equivalents at end of period（\(4) Results of Operations byBusiness Segment:（Net sales
Basic Chemicals
Petrochemicals & Plastics
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
Others\\Operating income
Basic Chemicals
Petrochemicals & Plastics
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersAdjustments\\（$152,320
340,993
148,588
138,521
193,181
24,678998,281$

12,524
7,795
10,083
14,77815,456
3,502(10,103)
54,035

$

$

$(22)

（\Yen）
1,523

78\3,000US$*1

US$ 1,000 ）
60,705（\1,987,215
4,448,702
1,938,526
1,807,189
2,520,300
321,956
13,023,888\

163,392
101,696
131,546
192,798
201,644
45,688(131,806)
704,958\\\(Note)*1:U.S. dollar amounts are translated from yen, for convenience only, at the rate of¥76.65= $1 prevailing on September 30, 2011.
*2:New business segmentation is applied to consolidated financial results of the previous fiscal year.

\ Million ）(35,014)

152,681
317,454
163,948
125,829
204,641
24,692989,245
11,771
5,763
17,146
14,366
14,663856(11,522)53,043